HR-/HER2+

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

HR-/HER2+

Aug 8, 2024, 10:01 | Blog

Sergio Cifuentes Canaval: How NACT compares to adjuvant chemotherapy for patients with HR+/HER2− breast cancer

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT Mexico, shared on LinkedIn about recent…

Aug 2, 2024, 02:02 | Blog

Sergio Cifuentes Canaval: Impact of CDK4/6 Inhibitors on Brain Metastases in HR+/HER2- Metastatic Breast Cancer

Sergio Cifuentes Canaval, Cancer Research Project Manager at CENEIT Mexico, shared on LinkedIn about recent…

Jul 16, 2024, 14:12 | Blog

Elisabetta Bonzano: Comparative biological activity of palbociclib and ribociclib in HR+ breast cancer

Elisabetta Bonzano, Associate Professor at MIUR, shared on X: "Comparative biological activity of palbociclib and…

Jun 23, 2024, 13:08 | Drugs

Capivasertib is now approved in EU for HR+/HER2- breast cancer

Paolo Tarantino shared a post on X: "Capivasertib is now approved in EU for the…

May 26, 2024, 13:42 | Insight

Some of the highlights while waiting for ASCO24 by Yakup Ergün

Yakup Ergün, Medical Oncologist at Ankara Numune Training and Research Hospital, shared a post on…

Apr 8, 2024, 15:49 | Insight

Paolo Tarantino: The TRAIN3 trial of MRI-guided TCHP is out in The Lancet Oncology

Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, recently shared on X: "The TRAIN3…

All: 6 Posts: 1 - 100